TY - JOUR
T1 - Characteristics of mycoplasma genitalium urogenital infections in a diverse patient sample from the United States
T2 - Results from the aptima mycoplasma genitalium evaluation study (AMES)
AU - behalf of the AMES Clinical Study Group
AU - Manhart, Lisa E.
AU - Gaydos, Charlotte A.
AU - Taylor, Stephanie N.
AU - Lillis, Rebecca A.
AU - Hook, Edward W.
AU - Klausner, Jeffrey D.
AU - Remillard, Carmelle V.
AU - Love, Melissa
AU - McKinney, Byron
AU - Getman, Damon K.
AU - Beasley, Anitra
AU - Chavoustie, Steven
AU - Denham, Douglas
AU - Dombrowski, Julie
AU - Dunn, Michael
AU - Emery, Christopher
AU - Harper, Wayne
AU - Jones, Christopher
AU - Kinder, Clifford
AU - Lyons, Michael
AU - Miller, Joseph
AU - Rathore, Mobeen
AU - Shesser, Robert
AU - Shipp, Dane
AU - Spurrell, Timothy
AU - Trout, Wayne
AU - Workowski, Kimberly Ann
AU - Yamane, David
N1 - Publisher Copyright:
© 2020 Manhart et al. This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license.
PY - 2020/7
Y1 - 2020/7
N2 - Data from a large prospective multicenter clinical validation study of a nucleic acid amplification in vitro diagnostic test for Mycoplasma genitalium were analyzed to describe the prevalence of M. genitalium infection, risk factors, and disease associations in female and male patients seeking care in diverse geographic regions of the United States. Among 1,737 female and 1,563 male participants, the overall prevalence of M. genitalium infection was 10.3% and was significantly higher in persons ages 15 to 24 years than in persons ages 35 to 39 years (for females, 19.8% versus 4.7% [odds ratio {OR} = 5.05; 95% confidence interval {CI} = 3.01 to 8.46]; for males, 16.5% versus 9.4% [OR = 1.91; 95% CI = 1.20 to 3.02]). The risk for M. genitalium infection was higher in black than in white participants (for females, 12.0% versus 6.8% [OR = 1.88; 95% CI = 1.30 to 2.72]; for males, 12.9% versus 6.9% [OR = 2.02; 95% CI = 1.38 to 2.96]) and higher in non-Hispanic than in Hispanic participants (for females, 11.2% versus 6.0% [OR = 1.97; 95% CI = 1.25 to 3.10]; for males, 11.6% versus 6.8% [OR = 1.80; 95% CI = 1.14 to 2.85]). Participants reporting urogenital symptoms had a significantly elevated risk of M. genitalium infection compared to that for asymptomatic individuals (for females, OR = 1.53 [95% CI = 1.09 to 2.14]; for males, OR = 1.42 [95% CI = 1.02 to 1.99]). Women diagnosed with vaginitis and cervicitis had a higher prevalence of M. genitalium infection than women without those diagnoses, although this was statistically significant only for vaginitis (for vaginitis, OR = 1.88 [95% CI = 1.37 to 2.58]; for cervicitis, OR = 1.42 [95% CI = 0.61 to 2.96]). A diagnosis of urethritis in men was also significantly associated with M. genitalium infection (OR = 2.97; 95% CI = 2.14 to 4.13). Few characteristics distinguished asymptomatic from symptomatic M. genitalium infections. These results from persons seeking care in the United States suggest that M. genitalium infection should be considered in young persons presenting with urogenital symptoms.
AB - Data from a large prospective multicenter clinical validation study of a nucleic acid amplification in vitro diagnostic test for Mycoplasma genitalium were analyzed to describe the prevalence of M. genitalium infection, risk factors, and disease associations in female and male patients seeking care in diverse geographic regions of the United States. Among 1,737 female and 1,563 male participants, the overall prevalence of M. genitalium infection was 10.3% and was significantly higher in persons ages 15 to 24 years than in persons ages 35 to 39 years (for females, 19.8% versus 4.7% [odds ratio {OR} = 5.05; 95% confidence interval {CI} = 3.01 to 8.46]; for males, 16.5% versus 9.4% [OR = 1.91; 95% CI = 1.20 to 3.02]). The risk for M. genitalium infection was higher in black than in white participants (for females, 12.0% versus 6.8% [OR = 1.88; 95% CI = 1.30 to 2.72]; for males, 12.9% versus 6.9% [OR = 2.02; 95% CI = 1.38 to 2.96]) and higher in non-Hispanic than in Hispanic participants (for females, 11.2% versus 6.0% [OR = 1.97; 95% CI = 1.25 to 3.10]; for males, 11.6% versus 6.8% [OR = 1.80; 95% CI = 1.14 to 2.85]). Participants reporting urogenital symptoms had a significantly elevated risk of M. genitalium infection compared to that for asymptomatic individuals (for females, OR = 1.53 [95% CI = 1.09 to 2.14]; for males, OR = 1.42 [95% CI = 1.02 to 1.99]). Women diagnosed with vaginitis and cervicitis had a higher prevalence of M. genitalium infection than women without those diagnoses, although this was statistically significant only for vaginitis (for vaginitis, OR = 1.88 [95% CI = 1.37 to 2.58]; for cervicitis, OR = 1.42 [95% CI = 0.61 to 2.96]). A diagnosis of urethritis in men was also significantly associated with M. genitalium infection (OR = 2.97; 95% CI = 2.14 to 4.13). Few characteristics distinguished asymptomatic from symptomatic M. genitalium infections. These results from persons seeking care in the United States suggest that M. genitalium infection should be considered in young persons presenting with urogenital symptoms.
KW - Aptima
KW - Aptima Mycoplasma genitalium Evaluation Study (AMES)
KW - Epidemiology
KW - Mycoplasma genitalium
KW - Sexually transmitted infection
UR - http://www.scopus.com/inward/record.url?scp=85086909799&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85086909799&partnerID=8YFLogxK
U2 - 10.1128/JCM.00165-20
DO - 10.1128/JCM.00165-20
M3 - Article
C2 - 32321783
AN - SCOPUS:85086909799
SN - 0095-1137
VL - 58
JO - Journal of clinical microbiology
JF - Journal of clinical microbiology
IS - 7
M1 - e00165-20
ER -